Pedro Rosa-Neto
Overview
Explore the profile of Pedro Rosa-Neto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
338
Citations
9310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Smith E, Phillips N, Feldman H, Borrie M, Ganesh A, Henri-Bhargava A, et al.
J Prev Alzheimers Dis
. 2025 Feb;
12(3):100068.
PMID: 39893139
Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To...
12.
Da Ros L, Borelli W, Schaffer Aguzzoli C, De Bastiani M, Schilling L, Santamaria-Garcia H, et al.
Lancet Glob Health
. 2025 Jan;
13(2):e277-e284.
PMID: 39890228
Background: Latin American countries present major health-related inequities due to historical, cultural, and social aspects. Recent evidence highlights that factors related to social and health disparities outweigh classic demographic factors...
13.
Arias J, Brum W, Salvado G, Therriault J, Servaes S, Wang Y, et al.
Brain
. 2025 Jan;
PMID: 39879633
Plasma phosphorylated tau biomarkers open unprecedented opportunities for identifying carriers of Alzheimer's disease pathophysiology in early disease stages using minimally invasive techniques. Plasma p-tau biomarkers are believed to reflect tau...
14.
Wang Y, Ashton N, Therriault J, Benedet A, Macedo A, Pola I, et al.
Brain Commun
. 2025 Jan;
7(1):fcaf004.
PMID: 39845736
Blood-based biomarkers have been revolutionizing the detection, diagnosis and screening of Alzheimer's disease. Specifically, phosphorylated-tau variants (p-tau, p-tau and p-tau) are promising biomarkers for identifying Alzheimer's disease pathology. Antibody-based assays...
15.
Hosseini S, Servaes S, Hall B, Bhaduri S, Rajan A, Rosa-Neto P, et al.
Diagnostics (Basel)
. 2025 Jan;
15(1.
PMID: 39795566
: The accurate and early distinction of glioblastomas (GBMs) from single brain metastases (BMs) provides a window of opportunity for reframing treatment strategies enabling optimal and timely therapeutic interventions. We...
16.
Quispialaya K, Therriault J, Aliaga A, Benedet A, Ashton N, Karikari T, et al.
Neurology
. 2024 Dec;
104(2):e210211.
PMID: 39715476
Background And Objectives: To compare the diagnostic performance of an immunoassay for plasma concentrations of phosphorylated tau (p-tau) 217 with visual assessments of fluorine-18 fluorodeoxyglucose [F]FDG-PET in individuals who meet...
17.
Chertkow H, Phillips N, Rockwood K, Anderson N, Andrew M, Bartha R, et al.
J Alzheimers Dis
. 2024 Dec;
102(3):535-561.
PMID: 39636028
The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014,...
18.
Aumont E, Bedard M, Bussy A, Arias J, Tissot C, Hall B, et al.
Neurobiol Aging
. 2024 Dec;
146:48-57.
PMID: 39631245
In this longitudinal brain imaging study, we aimed to characterize hippocampal tau accumulation and subfield atrophy relative to cortical amyloid-β and memory performance. We measured tau-PET in regions associated with...
19.
Therriault J, Janelidze S, Benedet A, Ashton N, Arranz Martinez J, Gonzalez-Escalante A, et al.
Nat Aging
. 2024 Nov;
4(11):1529-1537.
PMID: 39533113
Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce...
20.
Woo M, Therriault J, Jonaitis E, Wilson R, Langhough R, Rahmouni N, et al.
EBioMedicine
. 2024 Nov;
109():105413.
PMID: 39500009
Background: Blood-based disease staging across the Alzheimer's disease (AD) continuum holds the promise to identify individuals that profit from disease-modifying therapies. We set out to identify Braak V (Braak V...